Small Cap Biotechs Lead The Market In 2019 Up 20% YTD

Update: 1:40 EST 2/25

Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE​; and XBI up 4.2%.

Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%.

==========

M&A Drives Mid and Small Cap Biotechs Stocks Higher

The Small Cap weighted XBI is up 20% YTD.

iShares Russell 2000 (IWM) is up 19.6% YTD to $158.15.

Healthcare Sector (XLV) is up 9.5% YTD.

Investors have a very short memory of the market free-fall in Q4 2018 because now we have recovered over 90% of Q4 losses on many market indices and even show gains over a 52 week period. We vaguely remember the reasons for last year’s tumble but many analysts attributed the sell-off to the FED and the concern about rising rates and of course daily geopolitical headlines. Nothing much has changed except the FED talk has become more benign and we are more optimistic with a temporary trade truce with China. Even if a minor trade deal is closed we may have averted a disastrous global trade war. But looking ahead we have some tough hurdles with a March 29 Brexit deadline and the Robert Muller III report on Russia’s influence in the 2016 election.

Small Caps Recover in 2019

Small and Mid-Cap Biotechs Are M&A Targets

We have come very far in 2019 with little earnings support from large cap biopharma and a lot of revenue growth from price increases. But several major deals have closed in 2019 with two over the past week.

  • Roche Holding (RHHBY) is one of our core large cap holdings and is up 13% YTD; Roche is in the final stages (see WSJ) of acquiring Spark Therapeutics for about $5B. Spark (ONCE) is a gene therapy Company with a pipeline of products targeting blindness, hemophilia and neurodegenerative diseases. ONCE shares closed at $51.56 on Friday (up 35% YTD)so look for a move up on Monday since the market cap is only $1.94B.
  • Merck (MRK) another large cap core holding bought micro-cap Company Immune Design (IMDZ) for $300M in cash or $5.85/sh a 312% increase from the 2/20 closing. IMDZ is a clinical stage immunotherapy focused in cancer with a Phase 2 TLR4 agonist and a Phase 2 RSV vaccine. The Company has two unique drug discovery platforms.
  • Earlier this year BristolMyers (BMY) bought Celgene (CELG) for $74B nd Loxo Oncology (LOXO) was picked up by Lilly (LLY) fo $8B.
1 2
View single page >> |

Disclosure: I am long AMRN BMY CELG GNMK TDOC

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.